Italiano
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#immunoonc risultati di ricerca

mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
8 nov

Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma [Jan 30, 2023] @Eddie_Cliff et al. @JCO_ASCO ascopubs.org/doi/full/10.12… #mmsm #ImmunoOnc #IDonc

mtmdphd's tweet image. Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma [Jan 30, 2023] @Eddie_Cliff et al. @JCO_ASCO ascopubs.org/doi/full/10.12… #mmsm #ImmunoOnc #IDonc
0
3
4
2
1K
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
10 nov

Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (BiPE; LC Fibril x CD64) for AL amyloidosis [Nov 3, 2025] Fu et al. @SLentzsch #ASH25 abs25-3938 PID 3919 meetings-api.hematology.org/api/abstract/v… #caxtx #ImmunoOnc

mtmdphd's tweet image. Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (BiPE; LC Fibril x CD64) for AL amyloidosis [Nov 3, 2025] Fu et al. @SLentzsch #ASH25 abs25-3938 PID 3919 meetings-api.hematology.org/api/abstract/v… #caxtx #ImmunoOnc
0
1
5
0
295
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
12 nov

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma [DEMM] - an international myeloma working group [IMWG] immunotherapy database analysis [Nov 3, 2025] @JanakiramMurali et al. #ASH25 abs25-14454 PID 4598 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc

mtmdphd's tweet image. Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma [DEMM] - an international myeloma working group [IMWG] immunotherapy database analysis [Nov 3, 2025] @JanakiramMurali et al. #ASH25 abs25-14454 PID 4598 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc
0
3
6
2
402
VJOncology's profile picture. The Video Journal of Oncology is dedicated to providing up-to-date information & international expertise on #Oncology #BCsm #LCsm #GUsm #GIsm #PCsm #CRCsm
VJ Oncology
@VJOncology
15 nov

🎥Katarzyna Kozak, MD, PhD, discusses Phase II EFTISARC-NEO, where neoadjuvant eftilagimod alpha + pembrolizumab + RT increased tumor hyalinization/fibrosis in resectable STS, meeting its endpoint with manageable safety Watch ➡️ ow.ly/w3mA50XrAFY #ESMO25 #scmSM #ImmunoOnc…

VJOncology's tweet card. Katarzyna Kozak, MD, PhD, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, discusses the Phase II EFTISARC-NEO study (NCT06128863) of neoadjuvant eftilagimod alpha with...
EFTISARC-NEO: neoadjuvant eftilagimod alpha, pembrolizumab and RT in STS
Fonte: vjoncology.com
0
1
6
0
345
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
11 nov

Bi-specific T-cell engagers (BiTEs) as a bridge to cilta-cel in RRMM: Real-world outcomes in an underserved urban population [Nov 3, 2025] @beltranfsanti et al. #ASH25 abs25-8444 PID 4577 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #CancerDisparities

mtmdphd's tweet image. Bi-specific T-cell engagers (BiTEs) as a bridge to cilta-cel in RRMM: Real-world outcomes in an underserved urban population [Nov 3, 2025] @beltranfsanti et al. #ASH25 abs25-8444 PID 4577 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #CancerDisparities
0
0
3
0
372
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
10 nov

Talquetamab [GPRC5D BsAb] for RRMM : Real-world outcomes from the US multiple myeloma immunotherapy consortium [Nov 3, 2025] Pasvolsky et al. @YiLinMDPhD #ASH25 abs25-12771 PID 137 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #IDonc n=484 pts, 15 centers

mtmdphd's tweet image. Talquetamab [GPRC5D BsAb] for RRMM : Real-world outcomes from the US multiple myeloma immunotherapy consortium [Nov 3, 2025] Pasvolsky et al. @YiLinMDPhD #ASH25 abs25-12771 PID 137 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #IDonc n=484 pts, 15 centers
0
1
5
2
828
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
8 nov

Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. @BloodPortfolio ashpublications.org/bloodadvances/… #mmsm #ImmunoOnc #IDonc #LymphoidNeoplasia

mtmdphd's tweet image. Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. @BloodPortfolio ashpublications.org/bloodadvances/… #mmsm #ImmunoOnc #IDonc #LymphoidNeoplasia
0
0
4
0
309
ASCOPost's profile picture. News and views from the world of clinical oncology and hematology
The ASCO Post
 @ASCOPost
20 ott

New data from #ESMO25: Thymic health a marker for patient outcomes in #NSCLC treated with ICIs 📈 Higher thymic health scores associated with 35% lower risk of progression & 44% lower risk of death Presenter: Simon Bernatz MD @MassGenBrigham #immunoonc ascopost.com/news/october-2…

ASCOPost's tweet image. New data from #ESMO25: Thymic health a marker for patient outcomes in #NSCLC treated with ICIs 📈 Higher thymic health scores associated with 35% lower risk of progression & 44% lower risk of death Presenter: Simon Bernatz MD @MassGenBrigham #immunoonc ascopost.com/news/october-2…
1
1
4
0
930
ShannonWestin's profile picture. Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. @ASCO_JCO social media editor. Opinions=mine. https://t.co/QLXLDKSThc
Shannon Westin, MD, MPH, FASCO
 @ShannonWestin
22 ott 2023

👀Neoadjuvant #ImmunoOnc in advanced MMRd #EndometrialCancer yields response rate of 37.5% and two pt w/ pathologic complete response after 2 cycles of therapy - very intriguing! 🧐Small study - n=10 - will be interesting to see further data in this space #ESMO2023 #gyncsm

ShannonWestin's tweet image. 👀Neoadjuvant #ImmunoOnc in advanced MMRd #EndometrialCancer yields response rate of 37.5% and two pt w/ pathologic complete response after 2 cycles of therapy - very intriguing! 🧐Small study - n=10 - will be interesting to see further data in this space #ESMO2023 #gyncsm
ShannonWestin's tweet image. 👀Neoadjuvant #ImmunoOnc in advanced MMRd #EndometrialCancer yields response rate of 37.5% and two pt w/ pathologic complete response after 2 cycles of therapy - very intriguing! 🧐Small study - n=10 - will be interesting to see further data in this space #ESMO2023 #gyncsm
0
5
17
0
4K
FunchainMD's profile picture. Melanoma oncology. Study hereditary genetics and irAE. LA explant in SF via OH. Sports fan, geek, and mommy. COI https://t.co/UJ7zV936DV 🦋@funchainmd.bsky.social
Pauline Funchain
 @FunchainMD
28 feb

Good morning Cary NC 🌞 ASPirE 2025 starting now! #irAE #immunoonc @afreenshariffmd

FunchainMD's tweet image. Good morning Cary NC 🌞 ASPirE 2025 starting now! #irAE #immunoonc @afreenshariffmd
FunchainMD's tweet image. Good morning Cary NC 🌞 ASPirE 2025 starting now! #irAE #immunoonc @afreenshariffmd
0
2
14
0
2K
DAVAOnc's profile picture. DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
DAVA Oncology
 @DAVAOnc
28 giu

Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung

DAVAOnc's tweet image. Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung
DAVAOnc's tweet image. Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung
DAVAOnc's tweet image. Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung
DAVAOnc's tweet image. Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung
0
3
15
0
1K
VJOncology's profile picture. The Video Journal of Oncology is dedicated to providing up-to-date information & international expertise on #Oncology #BCsm #LCsm #GUsm #GIsm #PCsm #CRCsm
VJ Oncology
@VJOncology
18 nov

Ryan Sullivan, MD (@MassGenBrigham), discusses IMcode001 in advanced melanoma. 🧬 mRNA neoantigen vaccine + pembrolizumab 📉 No PFS improvement vs pembrolizumab alone 💥 Strong immune responses in most patients 🎥 ow.ly/OqR450XsMCT #Melanoma #Immunotherapy #ImmunoOnc…

VJOncology's tweet card. Ryan Sullivan, MD, Massachusetts General Hospital, Boston, MA, explores findings from the Phase II IMcode001 study (NCT03815058) of autogene cevumeran, an individualized neoantigen-specific mRNA...
IMcode001: autogene cevumeran & pembrolizumab in melanoma
Fonte: vjoncology.com
0
0
1
0
186
VJOncology's profile picture. The Video Journal of Oncology is dedicated to providing up-to-date information & international expertise on #Oncology #BCsm #LCsm #GUsm #GIsm #PCsm #CRCsm
VJ Oncology
@VJOncology
15 nov

🎥Katarzyna Kozak, MD, PhD, discusses Phase II EFTISARC-NEO, where neoadjuvant eftilagimod alpha + pembrolizumab + RT increased tumor hyalinization/fibrosis in resectable STS, meeting its endpoint with manageable safety Watch ➡️ ow.ly/w3mA50XrAFY #ESMO25 #scmSM #ImmunoOnc…

VJOncology's tweet card. Katarzyna Kozak, MD, PhD, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, discusses the Phase II EFTISARC-NEO study (NCT06128863) of neoadjuvant eftilagimod alpha with...
EFTISARC-NEO: neoadjuvant eftilagimod alpha, pembrolizumab and RT in STS
Fonte: vjoncology.com
0
1
6
0
345
VJOncology's profile picture. The Video Journal of Oncology is dedicated to providing up-to-date information & international expertise on #Oncology #BCsm #LCsm #GUsm #GIsm #PCsm #CRCsm
VJ Oncology
@VJOncology
13 nov

@MImbimbo1 (@EnteOspedaliero) discusses early results from the EXPAND-1 trial of ANV600, a PD-1–targeted IL-2Rβ/γ agonist showing manageable safety and potential in checkpoint-refractory tumors. 🎥 Watch: ow.ly/JxZJ50XqEwR #ESMO25 #ImmunoOnc #CTSM #TrialUpdate #Oncology

VJOncology's tweet card. Martina Imbimbo, MD, Ente Ospedaliero Cantonale, Lugano, Switzerland, describes the Phase I/II EXPAND-1 study (NCT06470763) of ANV600, a PD-1–targeted IL-2Rβ/γ agonist, as monotherapy and in combin...
EXPAND-1: Phase I/II study of ANV600 in advanced solid tumors
Fonte: vjoncology.com
0
0
0
0
37
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
12 nov

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma [DEMM] - an international myeloma working group [IMWG] immunotherapy database analysis [Nov 3, 2025] @JanakiramMurali et al. #ASH25 abs25-14454 PID 4598 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc

mtmdphd's tweet image. Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma [DEMM] - an international myeloma working group [IMWG] immunotherapy database analysis [Nov 3, 2025] @JanakiramMurali et al. #ASH25 abs25-14454 PID 4598 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc
0
3
6
2
402
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
11 nov

Bi-specific T-cell engagers (BiTEs) as a bridge to cilta-cel in RRMM: Real-world outcomes in an underserved urban population [Nov 3, 2025] @beltranfsanti et al. #ASH25 abs25-8444 PID 4577 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #CancerDisparities

mtmdphd's tweet image. Bi-specific T-cell engagers (BiTEs) as a bridge to cilta-cel in RRMM: Real-world outcomes in an underserved urban population [Nov 3, 2025] @beltranfsanti et al. #ASH25 abs25-8444 PID 4577 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #CancerDisparities
0
0
3
0
372
VJOncology's profile picture. The Video Journal of Oncology is dedicated to providing up-to-date information & international expertise on #Oncology #BCsm #LCsm #GUsm #GIsm #PCsm #CRCsm
VJ Oncology
@VJOncology
10 nov

🎥@DrTFriedlander (@UCSF) shares 3.5-year #EV103 Cohort K data at #ESMO25 🌟Enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC. Watch ➡️ ow.ly/VmtA50XpeLQ #ImmunoOnc #UroOnc #UroSoMe #Blcsm #CTSM #TrialUpdate @myESMO

VJOncology's tweet card. Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103 study (NCT03288545), which assessed enfortumab vedotin (EV)...
EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC
Fonte: vjoncology.com
0
0
0
0
232
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
10 nov

Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (BiPE; LC Fibril x CD64) for AL amyloidosis [Nov 3, 2025] Fu et al. @SLentzsch #ASH25 abs25-3938 PID 3919 meetings-api.hematology.org/api/abstract/v… #caxtx #ImmunoOnc

mtmdphd's tweet image. Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (BiPE; LC Fibril x CD64) for AL amyloidosis [Nov 3, 2025] Fu et al. @SLentzsch #ASH25 abs25-3938 PID 3919 meetings-api.hematology.org/api/abstract/v… #caxtx #ImmunoOnc
0
1
5
0
295
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
10 nov

Talquetamab [GPRC5D BsAb] for RRMM : Real-world outcomes from the US multiple myeloma immunotherapy consortium [Nov 3, 2025] Pasvolsky et al. @YiLinMDPhD #ASH25 abs25-12771 PID 137 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #IDonc n=484 pts, 15 centers

mtmdphd's tweet image. Talquetamab [GPRC5D BsAb] for RRMM : Real-world outcomes from the US multiple myeloma immunotherapy consortium [Nov 3, 2025] Pasvolsky et al. @YiLinMDPhD #ASH25 abs25-12771 PID 137 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #IDonc n=484 pts, 15 centers
0
1
5
2
828
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
8 nov

Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. @BloodPortfolio ashpublications.org/bloodadvances/… #mmsm #ImmunoOnc #IDonc #LymphoidNeoplasia

mtmdphd's tweet image. Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. @BloodPortfolio ashpublications.org/bloodadvances/… #mmsm #ImmunoOnc #IDonc #LymphoidNeoplasia
0
0
4
0
309
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
8 nov

Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma [Jan 30, 2023] @Eddie_Cliff et al. @JCO_ASCO ascopubs.org/doi/full/10.12… #mmsm #ImmunoOnc #IDonc

mtmdphd's tweet image. Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma [Jan 30, 2023] @Eddie_Cliff et al. @JCO_ASCO ascopubs.org/doi/full/10.12… #mmsm #ImmunoOnc #IDonc
0
3
4
2
1K
ShannonWestin's profile picture. Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. @ASCO_JCO social media editor. Opinions=mine. https://t.co/QLXLDKSThc
Shannon Westin, MD, MPH, FASCO
 @ShannonWestin
22 ott 2023

👀Neoadjuvant #ImmunoOnc in advanced MMRd #EndometrialCancer yields response rate of 37.5% and two pt w/ pathologic complete response after 2 cycles of therapy - very intriguing! 🧐Small study - n=10 - will be interesting to see further data in this space #ESMO2023 #gyncsm

ShannonWestin's tweet image. 👀Neoadjuvant #ImmunoOnc in advanced MMRd #EndometrialCancer yields response rate of 37.5% and two pt w/ pathologic complete response after 2 cycles of therapy - very intriguing! 🧐Small study - n=10 - will be interesting to see further data in this space #ESMO2023 #gyncsm
ShannonWestin's tweet image. 👀Neoadjuvant #ImmunoOnc in advanced MMRd #EndometrialCancer yields response rate of 37.5% and two pt w/ pathologic complete response after 2 cycles of therapy - very intriguing! 🧐Small study - n=10 - will be interesting to see further data in this space #ESMO2023 #gyncsm
0
5
17
0
4K
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
8 nov

Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. @BloodPortfolio ashpublications.org/bloodadvances/… #mmsm #ImmunoOnc #IDonc #LymphoidNeoplasia

mtmdphd's tweet image. Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. @BloodPortfolio ashpublications.org/bloodadvances/… #mmsm #ImmunoOnc #IDonc #LymphoidNeoplasia
0
0
4
0
309
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
10 nov

Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (BiPE; LC Fibril x CD64) for AL amyloidosis [Nov 3, 2025] Fu et al. @SLentzsch #ASH25 abs25-3938 PID 3919 meetings-api.hematology.org/api/abstract/v… #caxtx #ImmunoOnc

mtmdphd's tweet image. Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (BiPE; LC Fibril x CD64) for AL amyloidosis [Nov 3, 2025] Fu et al. @SLentzsch #ASH25 abs25-3938 PID 3919 meetings-api.hematology.org/api/abstract/v… #caxtx #ImmunoOnc
0
1
5
0
295
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
14 ott

Immune cells display an abnormal maturation and a proinflammatory profile in telomere biology disorders [Sep 24, 2025] Gomes et al. Blood Advances @BloodPortfolio ashpublications.org/bloodadvances/… #ImmunoOnc

mtmdphd's tweet image. Immune cells display an abnormal maturation and a proinflammatory profile in telomere biology disorders [Sep 24, 2025] Gomes et al. Blood Advances @BloodPortfolio ashpublications.org/bloodadvances/… #ImmunoOnc
0
3
9
2
2K
JCO_ASCO's profile picture. @ASCO's credible, authoritative resource for disseminating clinical oncology research. Home of @JCOOP_ASCO, @JCOGO_ASCO, @JCOCCI_ASCO, @JCOPO_ASCO, @JCOOA_ASCO.
Journal of Clinical Oncology
@JCO_ASCO
27 dic 2023

😞 In SKYSCRAPER-02, tiragolumab + atezolizumab + chemo did not show improved progression free or overall survival compared to the placebo combo in pts with Extensive-Stage Small-Cell #LungCancer ➡️ brnw.ch/21wFDWN #LCSM #ImmunoOnc @charlesrudin

JCO_ASCO's tweet image. 😞 In SKYSCRAPER-02, tiragolumab + atezolizumab + chemo did not show improved progression free or overall survival compared to the placebo combo in pts with Extensive-Stage Small-Cell #LungCancer ➡️ brnw.ch/21wFDWN #LCSM #ImmunoOnc @charlesrudin
1
8
22
3
6K
FunchainMD's profile picture. Melanoma oncology. Study hereditary genetics and irAE. LA explant in SF via OH. Sports fan, geek, and mommy. COI https://t.co/UJ7zV936DV 🦋@funchainmd.bsky.social
Pauline Funchain
 @FunchainMD
28 feb

Good morning Cary NC 🌞 ASPirE 2025 starting now! #irAE #immunoonc @afreenshariffmd

FunchainMD's tweet image. Good morning Cary NC 🌞 ASPirE 2025 starting now! #irAE #immunoonc @afreenshariffmd
FunchainMD's tweet image. Good morning Cary NC 🌞 ASPirE 2025 starting now! #irAE #immunoonc @afreenshariffmd
0
2
14
0
2K
MolOncology's profile picture. Open access journal highlighting new discoveries, technical developments and policies in basic, translational, and clinical cancer research. Part of FEBS Press.
Molecular Oncology
@MolOncology
12 ago 2024

🌅August Issue is online🧴⛱️ 🎯Focus on the tumour microenvironment, the immune system and cell metabolism interaction, in relation to various therapeutic approaches utilised for the treatment of cancer 🏊‍♀️Dive in 🔓buff.ly/3SHud85 #CancerMetabolism #TME #ImmunoOnc

MolOncology's tweet image. 🌅August Issue is online🧴⛱️ 🎯Focus on the tumour microenvironment, the immune system and cell metabolism interaction, in relation to various therapeutic approaches utilised for the treatment of cancer 🏊‍♀️Dive in 🔓buff.ly/3SHud85 #CancerMetabolism #TME #ImmunoOnc
0
2
5
1
3K
JCO_ASCO's profile picture. @ASCO's credible, authoritative resource for disseminating clinical oncology research. Home of @JCOOP_ASCO, @JCOGO_ASCO, @JCOCCI_ASCO, @JCOPO_ASCO, @JCOOA_ASCO.
Journal of Clinical Oncology
@JCO_ASCO
30 ago 2023

👍 Durable anti-tumor activity to atezolizumab seen in a subset of patients w/ advanced #PenileCancer ➡️ brnw.ch/21wC7Dy #ImmunoOnc #radonc @Hielke_Martijn

JCO_ASCO's tweet image. 👍 Durable anti-tumor activity to atezolizumab seen in a subset of patients w/ advanced #PenileCancer ➡️ brnw.ch/21wC7Dy #ImmunoOnc #radonc @Hielke_Martijn
0
5
16
2
5K
ASCOPost's profile picture. News and views from the world of clinical oncology and hematology
The ASCO Post
 @ASCOPost
20 ott

New data from #ESMO25: Thymic health a marker for patient outcomes in #NSCLC treated with ICIs 📈 Higher thymic health scores associated with 35% lower risk of progression & 44% lower risk of death Presenter: Simon Bernatz MD @MassGenBrigham #immunoonc ascopost.com/news/october-2…

ASCOPost's tweet image. New data from #ESMO25: Thymic health a marker for patient outcomes in #NSCLC treated with ICIs 📈 Higher thymic health scores associated with 35% lower risk of progression & 44% lower risk of death Presenter: Simon Bernatz MD @MassGenBrigham #immunoonc ascopost.com/news/october-2…
1
1
4
0
930
JCO_ASCO's profile picture. @ASCO's credible, authoritative resource for disseminating clinical oncology research. Home of @JCOOP_ASCO, @JCOGO_ASCO, @JCOCCI_ASCO, @JCOPO_ASCO, @JCOOA_ASCO.
Journal of Clinical Oncology
@JCO_ASCO
30 dic 2023

🙌 Prospective study of chemo-free treatment with pembro + RT for biomarker-selected locally advanced non-small cell #LungCancer ➡️ brnw.ch/21wFHxj #LCSM #ImmunoOnc @nitinohri @DrSteveMartin

JCO_ASCO's tweet image. 🙌 Prospective study of chemo-free treatment with pembro + RT for biomarker-selected locally advanced non-small cell #LungCancer ➡️ brnw.ch/21wFHxj #LCSM #ImmunoOnc @nitinohri @DrSteveMartin
1
19
43
15
16K
MolOncology's profile picture. Open access journal highlighting new discoveries, technical developments and policies in basic, translational, and clinical cancer research. Part of FEBS Press.
Molecular Oncology
@MolOncology
19 ago 2024

⛱️Don't miss our August Issue🧴 🎯Focus on the TME, the immune system and cell metabolism interaction, in relation to various therapeutic approaches utilised for the treatment of cancer 🏊‍♀️Dive in 🔓buff.ly/3SHud85 #ImmunoOnc #Microenvironment #OncoImmunology

MolOncology's tweet image. ⛱️Don't miss our August Issue🧴 🎯Focus on the TME, the immune system and cell metabolism interaction, in relation to various therapeutic approaches utilised for the treatment of cancer 🏊‍♀️Dive in 🔓buff.ly/3SHud85 #ImmunoOnc #Microenvironment #OncoImmunology
0
4
7
0
542
JCO_ASCO's profile picture. @ASCO's credible, authoritative resource for disseminating clinical oncology research. Home of @JCOOP_ASCO, @JCOGO_ASCO, @JCOCCI_ASCO, @JCOPO_ASCO, @JCOOA_ASCO.
Journal of Clinical Oncology
@JCO_ASCO
29 set 2023

👍 Atezolizumab combined w/ carboplatin and pemetrexed demonstrated efficacy and safety in advanced non-squamous cell #LungCancer with untreated brain metastases ➡️ brnw.ch/21wD4Hs #ImmunoOnc #LCSM @NadalErnest

JCO_ASCO's tweet image. 👍 Atezolizumab combined w/ carboplatin and pemetrexed demonstrated efficacy and safety in advanced non-squamous cell #LungCancer with untreated brain metastases ➡️ brnw.ch/21wD4Hs #ImmunoOnc #LCSM @NadalErnest
0
10
29
3
9K
JCO_ASCO's profile picture. @ASCO's credible, authoritative resource for disseminating clinical oncology research. Home of @JCOOP_ASCO, @JCOGO_ASCO, @JCOCCI_ASCO, @JCOPO_ASCO, @JCOOA_ASCO.
Journal of Clinical Oncology
@JCO_ASCO
3 ott 2023

🙌 @ASCO #TAPUR results of pembrolizumab in multiple tumors w/ high #TumorMutationalBurden extends KEYNOTE-158 data that led to prior @FDA approval ➡️ brnw.ch/21wDapC #ImmunoOnc

JCO_ASCO's tweet image. 🙌 @ASCO #TAPUR results of pembrolizumab in multiple tumors w/ high #TumorMutationalBurden extends KEYNOTE-158 data that led to prior @FDA approval ➡️ brnw.ch/21wDapC #ImmunoOnc
0
7
23
6
8K
mtmdphd's profile picture. #MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://t.co/A6GQmWYvau
Mike Thompson, MD, PhD, FASCO
@mtmdphd
10 nov

Talquetamab [GPRC5D BsAb] for RRMM : Real-world outcomes from the US multiple myeloma immunotherapy consortium [Nov 3, 2025] Pasvolsky et al. @YiLinMDPhD #ASH25 abs25-12771 PID 137 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #IDonc n=484 pts, 15 centers

mtmdphd's tweet image. Talquetamab [GPRC5D BsAb] for RRMM : Real-world outcomes from the US multiple myeloma immunotherapy consortium [Nov 3, 2025] Pasvolsky et al. @YiLinMDPhD #ASH25 abs25-12771 PID 137 meetings-api.hematology.org/api/abstract/v… #mmsm #ImmunoOnc #IDonc n=484 pts, 15 centers
0
1
5
2
828
DAVAOnc's profile picture. DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
DAVA Oncology
 @DAVAOnc
28 giu

Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung

DAVAOnc's tweet image. Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung
DAVAOnc's tweet image. Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung
DAVAOnc's tweet image. Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung
DAVAOnc's tweet image. Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAP–TEAD axis targeting with IAG933, a first‐in‐human TEAD inhibitor showing early anti‐tumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung
0
3
15
0
1K

Something went wrong.


Something went wrong.


United States Trends